<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

The Cancer Letter

Pazdur Waxes On Calumet City And Krebiozen; Parkinson Takes Interim CMO Job at Zyngenia

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

Researchers Link Cancer Risk And DMPA Birth Control Use

Breast-Conserving Procedures Lead To Frequent Follow-up Care

False-Positive Mammograms Can Indicate Higher Cancer Risk

Proposed Surveillance Model Aims To Reduce Post-Treatment Pain

Adding Avastin Did Not Improve Standard Chemotherapy Regimen

Ibrutinib Demonstrates Responses In Large B-Cell Lymphomas

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

Perifosine Fails Primary Endpoint, Zentaris CEO Explores Options